Respiratory Cancers

The role of fibroblast growth factor 9 (FGF9)

The role of fibroblast growth factor 9 (FGF9)

Researchers at the Institute for Respiratory Health employ various in vitro techniques and preclinical models to investigate novel therapies for malignant pleural disease and mesothelioma.

FGF-9 is an exciting and novel target uncovered from global gene profiling of human malignant pleural mesothelioma (MPM) samples.

Researcher have verified over-expression of FGF-9 in MPM over other cancers and benign pleuritis in five separate cohorts of human pleural tissues and effusions. Preliminary in vitro work shows that FGF-9 induces mesothelioma cell proliferation and matrix invasion, and knock-down of FGF-9 retards MPM growth in mice.

This data is the first to suggest a central role of FGF-9 in the biology of MPM and current studies are aimed at assessing anti-FGF-9 strategies for clinical translation. In addition, findings show that FGF-9 inhibits the antitumour immune response in mesothelioma. We are currently determining the mechanism for this novel role for FGF-9.

To get involved or for more information, contact the Research Leader.

The role of fibroblast growth factor 9 (FGF9) was last modified: May 12th, 2016 by Sarah Cermak

Research Leaders

Dr Sally Lansley

BSc, PhD

Senior Research Fellow

sally.lansley@resphealth.uwa.edu.au
LinkedIn

Dr Sally Lansley was last modified: December 20th, 2016 by Sarah Cermak

Prof Gary Lee

MBChB, PhD, FRACP, FRCP, FCCP

Head of Pleural Medicine Group

gary.lee@health.wa.gov.au
LinkedIn

Prof Gary Lee was last modified: February 24th, 2017 by Sarah Cermak

The role of fibroblast growth factor 9 (FGF9) was last modified: May 12th, 2016 by Sarah Cermak